BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campos AI, Byrne EM, Mitchell BL, Wray NR, Lind PA, Licinio J, Medland SE, Martin NG, Hickie IB, Rentería ME. Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study. Pharmacogenomics J 2022;22:130-5. [PMID: 35094016 DOI: 10.1038/s41397-022-00267-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ricardo-Silgado ML, Singh S, Cifuentes L, Decker PA, Gonzalez-Izundegui D, Moyer AM, Hurtado MD, Camilleri M, Bielinski SJ, Acosta A. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. BMC Med 2022;20:261. [PMID: 35879764 DOI: 10.1186/s12916-022-02433-x] [Reference Citation Analysis]
2 Thiele LS, Ishtiak-ahmed K, Thirstrup JP, Agerbo E, Lunenburg CATC, Müller DJ, Gasse C. Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study. Pharmaceuticals 2022;15:870. [DOI: 10.3390/ph15070870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Joković D, Milosavljević F, Stojanović Z, Šupić G, Vojvodić D, Uzelac B, Jukić MM, Petković Ćurčin A. CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability. Psychiatry Research 2022;312:114535. [DOI: 10.1016/j.psychres.2022.114535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]